FDA.reportPublic FDA data

15 ML daratumumab-fihj 120 MG/ML / hyaluronidase-fihj 2000 UNT/ML Injection [Darzalex Faspro]

RxCUI
2375141
RxNorm name
15 ML daratumumab-fihj 120 MG/ML / hyaluronidase-fihj 2000 UNT/ML Injection [Darzalex Faspro]
Display name
15 ML daratumumab-fihj 120 MG/ML / hyaluronidase-fihj 2000 UNT/ML Injection [Darzalex Faspro]
Full name
15 ML daratumumab-fihj 120 MG/ML / hyaluronidase-fihj 2000 UNT/ML Injection [Darzalex Faspro]
Term type
SBD
Status
DailyMed mapping
Updated
2026-06-04 23:38:57

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761145Darzalex Fasprodaratumumab and hyaluronidase-fihj351(a)Rx2026-06-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Darzalex FasproDARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT)Janssen Biotech, Inc.4bb241af-4299-4373-8762-2d6709515db02026-02-11Warnings, Adverse reactionsExact identifier
rxcui: 2375141

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
4bb241af-4299-4373-8762-2d6709515db015 ML daratumumab-fihj 120 MG/ML / hyaluronidase-fihj 2000 UNT/ML Injection [Darzalex Faspro]SBD31These highlights do not include all the information needed to use DARZALEX FASPRO safely and effectively. See full prescribing information for DARZALEX FASPRO. DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) injection, for subcutaneous use Initial U.S. Approval: 202020260211
4bb241af-4299-4373-8762-2d6709515db0DARZALEX Faspro 1800 MG / 30,000 UNT in 15 mL InjectionPSN31These highlights do not include all the information needed to use DARZALEX FASPRO safely and effectively. See full prescribing information for DARZALEX FASPRO. DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) injection, for subcutaneous use Initial U.S. Approval: 202020260211
4bb241af-4299-4373-8762-2d6709515db0DARZALEX Faspro 1800 MG / 30,000 UNT per 15 mL InjectionSY31These highlights do not include all the information needed to use DARZALEX FASPRO safely and effectively. See full prescribing information for DARZALEX FASPRO. DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) injection, for subcutaneous use Initial U.S. Approval: 202020260211
4bb241af-4299-4373-8762-2d6709515db0DARZALEX Faspro (daratumumab-hyaluronidase-fihj 1800 MG /30,000 UNT) per 15 ML InjectionSY31These highlights do not include all the information needed to use DARZALEX FASPRO safely and effectively. See full prescribing information for DARZALEX FASPRO. DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) injection, for subcutaneous use Initial U.S. Approval: 202020260211